Share Price and Basic Stock Data
Last Updated: February 1, 2026, 8:23 pm
| PEG Ratio | 1.79 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Artemis Medicare Services Ltd operates within the Hospitals & Medical Services industry, with its stock currently priced at ₹237 and a market capitalization of ₹3,753 Cr. The company’s revenue has shown significant growth, with reported sales rising from ₹563 Cr in March 2020 to ₹714 Cr in March 2023, and further to ₹913 Cr in March 2025. The trailing twelve months (TTM) sales stood at ₹981 Cr, indicating robust demand for its healthcare services. Quarterly sales also reflect this upward trajectory, with a notable increase from ₹182 Cr in September 2022 to ₹217 Cr in September 2023, and projected to reach ₹270 Cr by September 2025. This consistent growth trend underscores Artemis’s strategic positioning in a rapidly expanding healthcare market, bolstered by an increasing focus on health services post-pandemic and a growing middle-class population in India.
Profitability and Efficiency Metrics
Artemis Medicare has demonstrated commendable profitability metrics, with a reported net profit of ₹95 Cr for the TTM period, translating to an earnings per share (EPS) of ₹5.37. The company’s operating profit margin (OPM) has also improved, standing at 19% as of September 2023, compared to 13% in March 2022. This rise in profitability is complemented by a return on equity (ROE) of 12.9% and a return on capital employed (ROCE) of 14.9%, indicating effective utilization of equity and capital. The interest coverage ratio (ICR) of 5.78x signifies that the company can comfortably meet its interest obligations, reflecting solid operational efficiency. However, the cash conversion cycle (CCC) of 37 days, while manageable, suggests room for improvement in working capital management compared to industry standards, where lower CCC values are typically preferred.
Balance Sheet Strength and Financial Ratios
The balance sheet of Artemis Medicare indicates a stable financial position. The company reported total reserves of ₹873 Cr against borrowings of ₹274 Cr, showcasing a healthy capital structure with a low debt-to-equity ratio of 0.31x. This low leverage allows for greater financial flexibility and reduces risks associated with high debt levels. Additionally, the current ratio of 2.49x and quick ratio of 2.45x reflect a robust liquidity position, ensuring that the company can meet its short-term obligations. The price-to-book value (P/BV) ratio stands at 4.92x, which is relatively high, suggesting that investors are willing to pay a premium for the stock, possibly due to its growth prospects. However, the increasing interest expenses, which rose from ₹5 Cr in September 2022 to ₹8 Cr in March 2025, could exert pressure on profitability if not controlled.
Shareholding Pattern and Investor Confidence
As of November 2025, the shareholding pattern reveals a diverse investor base, with promoters holding 58.42% of the company. Foreign institutional investors (FIIs) have increased their stake to 12.48%, while domestic institutional investors (DIIs) hold 3.35%. The public’s share stands at 19.58%, with the number of shareholders increasing from 18,100 in March 2023 to 31,884 by November 2025, indicating growing investor interest. The gradual decline in promoter shareholding from 68.91% in March 2023 to 58.42% could raise concerns regarding control, but it may also reflect a strategic move to attract institutional capital. The increase in FII participation could signal confidence in the company’s growth potential and operational strategies, aligning with global trends in the healthcare sector.
Outlook, Risks, and Final Insight
Looking ahead, Artemis Medicare’s growth trajectory appears promising, driven by increasing healthcare demand and strategic expansions. However, risks remain, including potential regulatory changes in the healthcare sector and rising operational costs due to inflationary pressures. The company must also navigate competitive dynamics in the hospitals sector, where numerous players are vying for market share. Strengths such as a solid financial position, improving profitability metrics, and a growing institutional investor base provide a strong foundation for future growth. Conversely, risks associated with high valuation multiples and the potential for increased interest expenses could impact future profitability. Overall, while the company is well-positioned to capitalize on industry growth, it must remain vigilant in managing operational efficiencies and financial obligations to sustain its upward momentum.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 45.6 Cr. | 136 | 187/120 | 9.30 | 117 | 2.57 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 16.2 Cr. | 15.4 | 33.0/15.4 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 10.5 Cr. | 10.2 | 20.5/7.08 | 18.7 | 0.00 % | 3.00 % | 0.81 % | 10.0 | |
| Fortis Malar Hospitals Ltd | 105 Cr. | 55.9 | 98.7/52.2 | 23.1 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 19.6 Cr. | 3.62 | 6.42/3.28 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 24,718.86 Cr | 663.68 | 84.07 | 93.20 | 0.36% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 182 | 181 | 187 | 201 | 217 | 210 | 217 | 217 | 235 | 227 | 235 | 250 | 270 |
| Expenses | 158 | 156 | 163 | 174 | 184 | 179 | 181 | 181 | 193 | 190 | 199 | 209 | 220 |
| Operating Profit | 24 | 26 | 25 | 27 | 33 | 32 | 36 | 36 | 42 | 37 | 36 | 41 | 50 |
| OPM % | 13% | 14% | 13% | 14% | 15% | 15% | 17% | 16% | 18% | 16% | 15% | 16% | 19% |
| Other Income | 1 | 1 | 2 | 1 | 2 | 2 | 2 | 4 | 8 | 9 | 12 | 7 | 8 |
| Interest | 5 | 5 | 5 | 6 | 7 | 8 | 8 | 8 | 8 | 8 | 8 | 7 | 7 |
| Depreciation | 7 | 8 | 8 | 9 | 9 | 10 | 10 | 10 | 11 | 11 | 11 | 11 | 11 |
| Profit before tax | 14 | 14 | 14 | 13 | 19 | 16 | 19 | 22 | 31 | 27 | 29 | 30 | 40 |
| Tax % | 31% | 23% | 23% | 26% | 27% | 29% | 28% | 24% | 27% | 23% | 20% | 29% | 25% |
| Net Profit | 10 | 11 | 10 | 10 | 14 | 12 | 14 | 17 | 23 | 21 | 23 | 21 | 30 |
| EPS in Rs | 0.73 | 0.80 | 0.78 | 0.73 | 1.01 | 0.85 | 1.02 | 1.24 | 1.64 | 1.51 | 1.69 | 1.54 | 2.16 |
Last Updated: January 2, 2026, 11:00 am
Below is a detailed analysis of the quarterly data for Artemis Medicare Services Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 270.00 Cr.. The value appears strong and on an upward trend. It has increased from 250.00 Cr. (Jun 2025) to 270.00 Cr., marking an increase of 20.00 Cr..
- For Expenses, as of Sep 2025, the value is 220.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 209.00 Cr. (Jun 2025) to 220.00 Cr., marking an increase of 11.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 50.00 Cr.. The value appears strong and on an upward trend. It has increased from 41.00 Cr. (Jun 2025) to 50.00 Cr., marking an increase of 9.00 Cr..
- For OPM %, as of Sep 2025, the value is 19.00%. The value appears strong and on an upward trend. It has increased from 16.00% (Jun 2025) to 19.00%, marking an increase of 3.00%.
- For Other Income, as of Sep 2025, the value is 8.00 Cr.. The value appears strong and on an upward trend. It has increased from 7.00 Cr. (Jun 2025) to 8.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Sep 2025, the value is 7.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 7.00 Cr..
- For Depreciation, as of Sep 2025, the value is 11.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 11.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 40.00 Cr.. The value appears strong and on an upward trend. It has increased from 30.00 Cr. (Jun 2025) to 40.00 Cr., marking an increase of 10.00 Cr..
- For Tax %, as of Sep 2025, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 29.00% (Jun 2025) to 25.00%, marking a decrease of 4.00%.
- For Net Profit, as of Sep 2025, the value is 30.00 Cr.. The value appears strong and on an upward trend. It has increased from 21.00 Cr. (Jun 2025) to 30.00 Cr., marking an increase of 9.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 2.16. The value appears strong and on an upward trend. It has increased from 1.54 (Jun 2025) to 2.16, marking an increase of 0.62.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:38 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 261 | 368 | 402 | 459 | 503 | 547 | 563 | 402 | 545 | 714 | 845 | 913 | 981 |
| Expenses | 234 | 325 | 359 | 406 | 442 | 480 | 501 | 367 | 477 | 620 | 717 | 763 | 818 |
| Operating Profit | 27 | 43 | 43 | 53 | 60 | 66 | 62 | 35 | 68 | 94 | 128 | 150 | 163 |
| OPM % | 11% | 12% | 11% | 11% | 12% | 12% | 11% | 9% | 12% | 13% | 15% | 16% | 17% |
| Other Income | 1 | 3 | 5 | 4 | 3 | 2 | 4 | 7 | 3 | 7 | 7 | 33 | 36 |
| Interest | 13 | 12 | 9 | 9 | 9 | 11 | 13 | 12 | 11 | 19 | 30 | 30 | 29 |
| Depreciation | 9 | 12 | 12 | 15 | 18 | 20 | 22 | 21 | 21 | 29 | 38 | 43 | 44 |
| Profit before tax | 7 | 21 | 27 | 32 | 35 | 37 | 32 | 9 | 39 | 53 | 68 | 109 | 126 |
| Tax % | 0% | 12% | 21% | 16% | 24% | 44% | 36% | 20% | 16% | 25% | 28% | 24% | |
| Net Profit | 7 | 19 | 22 | 27 | 27 | 21 | 20 | 7 | 33 | 40 | 49 | 83 | 95 |
| EPS in Rs | 0.32 | 0.88 | 1.03 | 1.29 | 1.27 | 0.98 | 1.54 | 0.54 | 2.46 | 2.96 | 3.62 | 6.07 | 6.90 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 15% | 12% | 7% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 171.43% | 15.79% | 22.73% | 0.00% | -22.22% | -4.76% | -65.00% | 371.43% | 21.21% | 22.50% | 69.39% |
| Change in YoY Net Profit Growth (%) | 0.00% | -155.64% | 6.94% | -22.73% | -22.22% | 17.46% | -60.24% | 436.43% | -350.22% | 1.29% | 46.89% |
Artemis Medicare Services Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 10% |
| 3 Years: | 19% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 32% |
| 3 Years: | 36% |
| TTM: | 57% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 69% |
| 3 Years: | 53% |
| 1 Year: | -16% |
| Return on Equity | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 10% |
| 3 Years: | 12% |
| Last Year: | 13% |
Last Updated: September 4, 2025, 11:40 pm
Balance Sheet
Last Updated: December 4, 2025, 12:58 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 21 | 21 | 21 | 21 | 21 | 0.00 | 13 | 13 | 13 | 13 | 14 | 14 | 14 |
| Reserves | 116 | 135 | 163 | 183 | 210 | 280 | 301 | 308 | 348 | 393 | 438 | 828 | 873 |
| Borrowings | 110 | 85 | 68 | 94 | 91 | 114 | 108 | 137 | 190 | 268 | 305 | 280 | 274 |
| Other Liabilities | 66 | 90 | 93 | 124 | 130 | 160 | 159 | 130 | 145 | 207 | 191 | 221 | 255 |
| Total Liabilities | 313 | 331 | 345 | 422 | 452 | 555 | 581 | 589 | 697 | 882 | 948 | 1,343 | 1,416 |
| Fixed Assets | 236 | 239 | 249 | 283 | 309 | 381 | 387 | 372 | 476 | 584 | 699 | 729 | 780 |
| CWIP | 0 | 0 | 1 | 27 | 43 | 49 | 56 | 81 | 64 | 95 | 33 | 40 | 37 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 4 | 6 | 12 | 15 | 15 | 15 |
| Other Assets | 77 | 91 | 94 | 112 | 100 | 124 | 137 | 132 | 152 | 192 | 200 | 559 | 584 |
| Total Assets | 313 | 331 | 345 | 422 | 452 | 555 | 581 | 589 | 697 | 882 | 948 | 1,343 | 1,416 |
Below is a detailed analysis of the balance sheet data for Artemis Medicare Services Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 14.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 14.00 Cr..
- For Reserves, as of Sep 2025, the value is 873.00 Cr.. The value appears strong and on an upward trend. It has increased from 828.00 Cr. (Mar 2025) to 873.00 Cr., marking an increase of 45.00 Cr..
- For Borrowings, as of Sep 2025, the value is 274.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 280.00 Cr. (Mar 2025) to 274.00 Cr., marking a decrease of 6.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 255.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 221.00 Cr. (Mar 2025) to 255.00 Cr., marking an increase of 34.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,416.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,343.00 Cr. (Mar 2025) to 1,416.00 Cr., marking an increase of 73.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 780.00 Cr.. The value appears strong and on an upward trend. It has increased from 729.00 Cr. (Mar 2025) to 780.00 Cr., marking an increase of 51.00 Cr..
- For CWIP, as of Sep 2025, the value is 37.00 Cr.. The value appears to be declining and may need further review. It has decreased from 40.00 Cr. (Mar 2025) to 37.00 Cr., marking a decrease of 3.00 Cr..
- For Investments, as of Sep 2025, the value is 15.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 15.00 Cr..
- For Other Assets, as of Sep 2025, the value is 584.00 Cr.. The value appears strong and on an upward trend. It has increased from 559.00 Cr. (Mar 2025) to 584.00 Cr., marking an increase of 25.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,416.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,343.00 Cr. (Mar 2025) to 1,416.00 Cr., marking an increase of 73.00 Cr..
Notably, the Reserves (873.00 Cr.) exceed the Borrowings (274.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -83.00 | -42.00 | -25.00 | -41.00 | -31.00 | -48.00 | -46.00 | -102.00 | -122.00 | -174.00 | -177.00 | -130.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 41 | 39 | 49 | 48 | 40 | 52 | 50 | 48 | 47 | 43 | 36 | 37 |
| Inventory Days | 26 | 26 | 21 | 19 | ||||||||
| Days Payable | 237 | 195 | 189 | 187 | ||||||||
| Cash Conversion Cycle | -171 | -129 | -120 | -120 | 40 | 52 | 50 | 48 | 47 | 43 | 36 | 37 |
| Working Capital Days | -70 | -59 | -31 | -44 | -53 | -51 | -36 | -35 | -25 | -45 | -29 | -29 |
| ROCE % | 8% | 14% | 15% | 16% | 15% | 14% | 11% | 4% | 10% | 11% | 14% | 15% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HSBC Focused Fund | 1,250,000 | 1.97 | 33.88 | N/A | N/A | N/A |
| Bandhan Small Cap Fund | 609,551 | 0.09 | 16.52 | 421,079 | 2025-12-08 06:13:26 | 44.76% |
| LIC MF Small Cap Fund | 404,858 | 1.77 | 10.97 | 122,701 | 2025-12-08 02:25:41 | 229.95% |
| LIC MF Focused Fund | 199,852 | 3.14 | 5.42 | 206,004 | 2026-01-25 01:56:40 | -2.99% |
| LIC MF Healthcare Fund | 93,529 | 3.05 | 2.54 | 108,832 | 2025-12-15 00:16:01 | -14.06% |
| LIC MF Value Fund | 31,482 | 0.43 | 0.85 | 66,259 | 2026-01-25 01:56:40 | -52.49% |
| LIC MF Childrens Fund | 5,111 | 0.89 | 0.14 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 10.00 |
| Basic EPS (Rs.) | 5.37 | 3.62 | 2.89 | 2.40 | 4.90 |
| Diluted EPS (Rs.) | 5.31 | 3.53 | 2.79 | 2.29 | 4.90 |
| Cash EPS (Rs.) | 9.25 | 6.58 | 5.15 | 4.05 | 20.91 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 55.90 | 28.46 | 25.37 | 22.23 | 243.05 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 60.88 | 33.47 | 30.40 | 27.29 | 243.05 |
| Revenue From Operations / Share (Rs.) | 68.09 | 64.67 | 54.98 | 41.91 | 308.51 |
| PBDIT / Share (Rs.) | 13.43 | 10.31 | 7.55 | 5.39 | 29.26 |
| PBIT / Share (Rs.) | 10.15 | 7.34 | 5.24 | 3.71 | 13.01 |
| PBT / Share (Rs.) | 7.82 | 5.04 | 3.77 | 2.81 | 5.69 |
| Net Profit / Share (Rs.) | 5.97 | 3.62 | 2.83 | 2.37 | 4.65 |
| NP After MI And SOA / Share (Rs.) | 6.00 | 3.62 | 2.88 | 2.40 | 4.90 |
| PBDIT Margin (%) | 19.72 | 15.94 | 13.73 | 12.86 | 9.48 |
| PBIT Margin (%) | 14.90 | 11.35 | 9.53 | 8.86 | 4.21 |
| PBT Margin (%) | 11.49 | 7.79 | 6.86 | 6.70 | 1.84 |
| Net Profit Margin (%) | 8.77 | 5.59 | 5.15 | 5.65 | 1.50 |
| NP After MI And SOA Margin (%) | 8.81 | 5.59 | 5.23 | 5.73 | 1.58 |
| Return on Networth / Equity (%) | 10.74 | 12.91 | 11.49 | 10.87 | 2.02 |
| Return on Capital Employeed (%) | 12.23 | 12.67 | 10.05 | 8.60 | 3.57 |
| Return On Assets (%) | 6.08 | 5.05 | 4.26 | 4.48 | 1.08 |
| Long Term Debt / Equity (X) | 0.27 | 0.59 | 0.63 | 0.55 | 0.33 |
| Total Debt / Equity (X) | 0.31 | 0.66 | 0.71 | 0.62 | 0.33 |
| Asset Turnover Ratio (%) | 0.80 | 0.93 | 0.89 | 0.83 | 0.68 |
| Current Ratio (X) | 2.49 | 0.97 | 0.82 | 0.91 | 0.92 |
| Quick Ratio (X) | 2.45 | 0.92 | 0.75 | 0.82 | 0.84 |
| Inventory Turnover Ratio (X) | 93.41 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 7.45 | 12.44 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 4.82 | 6.83 | 0.00 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 92.55 | 87.56 | 0.00 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 95.18 | 93.17 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 5.78 | 4.48 | 5.15 | 5.96 | 3.00 |
| Interest Coverage Ratio (Post Tax) (X) | 3.57 | 2.57 | 2.93 | 3.62 | 1.23 |
| Enterprise Value (Cr.) | 3636.78 | 2505.47 | 1107.95 | 765.31 | 372.04 |
| EV / Net Operating Revenue (X) | 3.88 | 2.85 | 1.50 | 1.38 | 0.91 |
| EV / EBITDA (X) | 19.68 | 17.89 | 10.94 | 10.73 | 9.60 |
| MarketCap / Net Operating Revenue (X) | 4.04 | 2.63 | 1.24 | 1.10 | 0.71 |
| Retention Ratios (%) | 92.54 | 87.55 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 4.92 | 6.06 | 2.72 | 2.08 | 0.91 |
| Price / Net Operating Revenue (X) | 4.04 | 2.63 | 1.24 | 1.10 | 0.71 |
| EarningsYield | 0.02 | 0.02 | 0.04 | 0.05 | 0.02 |
After reviewing the key financial ratios for Artemis Medicare Services Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 5.37. This value is within the healthy range. It has increased from 3.62 (Mar 24) to 5.37, marking an increase of 1.75.
- For Diluted EPS (Rs.), as of Mar 25, the value is 5.31. This value is within the healthy range. It has increased from 3.53 (Mar 24) to 5.31, marking an increase of 1.78.
- For Cash EPS (Rs.), as of Mar 25, the value is 9.25. This value is within the healthy range. It has increased from 6.58 (Mar 24) to 9.25, marking an increase of 2.67.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 55.90. It has increased from 28.46 (Mar 24) to 55.90, marking an increase of 27.44.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 60.88. It has increased from 33.47 (Mar 24) to 60.88, marking an increase of 27.41.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 68.09. It has increased from 64.67 (Mar 24) to 68.09, marking an increase of 3.42.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 13.43. This value is within the healthy range. It has increased from 10.31 (Mar 24) to 13.43, marking an increase of 3.12.
- For PBIT / Share (Rs.), as of Mar 25, the value is 10.15. This value is within the healthy range. It has increased from 7.34 (Mar 24) to 10.15, marking an increase of 2.81.
- For PBT / Share (Rs.), as of Mar 25, the value is 7.82. This value is within the healthy range. It has increased from 5.04 (Mar 24) to 7.82, marking an increase of 2.78.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 5.97. This value is within the healthy range. It has increased from 3.62 (Mar 24) to 5.97, marking an increase of 2.35.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 6.00. This value is within the healthy range. It has increased from 3.62 (Mar 24) to 6.00, marking an increase of 2.38.
- For PBDIT Margin (%), as of Mar 25, the value is 19.72. This value is within the healthy range. It has increased from 15.94 (Mar 24) to 19.72, marking an increase of 3.78.
- For PBIT Margin (%), as of Mar 25, the value is 14.90. This value is within the healthy range. It has increased from 11.35 (Mar 24) to 14.90, marking an increase of 3.55.
- For PBT Margin (%), as of Mar 25, the value is 11.49. This value is within the healthy range. It has increased from 7.79 (Mar 24) to 11.49, marking an increase of 3.70.
- For Net Profit Margin (%), as of Mar 25, the value is 8.77. This value is within the healthy range. It has increased from 5.59 (Mar 24) to 8.77, marking an increase of 3.18.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 8.81. This value is within the healthy range. It has increased from 5.59 (Mar 24) to 8.81, marking an increase of 3.22.
- For Return on Networth / Equity (%), as of Mar 25, the value is 10.74. This value is below the healthy minimum of 15. It has decreased from 12.91 (Mar 24) to 10.74, marking a decrease of 2.17.
- For Return on Capital Employeed (%), as of Mar 25, the value is 12.23. This value is within the healthy range. It has decreased from 12.67 (Mar 24) to 12.23, marking a decrease of 0.44.
- For Return On Assets (%), as of Mar 25, the value is 6.08. This value is within the healthy range. It has increased from 5.05 (Mar 24) to 6.08, marking an increase of 1.03.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.27. This value is within the healthy range. It has decreased from 0.59 (Mar 24) to 0.27, marking a decrease of 0.32.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.31. This value is within the healthy range. It has decreased from 0.66 (Mar 24) to 0.31, marking a decrease of 0.35.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.80. It has decreased from 0.93 (Mar 24) to 0.80, marking a decrease of 0.13.
- For Current Ratio (X), as of Mar 25, the value is 2.49. This value is within the healthy range. It has increased from 0.97 (Mar 24) to 2.49, marking an increase of 1.52.
- For Quick Ratio (X), as of Mar 25, the value is 2.45. This value exceeds the healthy maximum of 2. It has increased from 0.92 (Mar 24) to 2.45, marking an increase of 1.53.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 93.41. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 93.41, marking an increase of 93.41.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 7.45. This value is below the healthy minimum of 20. It has decreased from 12.44 (Mar 24) to 7.45, marking a decrease of 4.99.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 4.82. This value is below the healthy minimum of 20. It has decreased from 6.83 (Mar 24) to 4.82, marking a decrease of 2.01.
- For Earning Retention Ratio (%), as of Mar 25, the value is 92.55. This value exceeds the healthy maximum of 70. It has increased from 87.56 (Mar 24) to 92.55, marking an increase of 4.99.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 95.18. This value exceeds the healthy maximum of 70. It has increased from 93.17 (Mar 24) to 95.18, marking an increase of 2.01.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.78. This value is within the healthy range. It has increased from 4.48 (Mar 24) to 5.78, marking an increase of 1.30.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.57. This value is within the healthy range. It has increased from 2.57 (Mar 24) to 3.57, marking an increase of 1.00.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,636.78. It has increased from 2,505.47 (Mar 24) to 3,636.78, marking an increase of 1,131.31.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.88. This value exceeds the healthy maximum of 3. It has increased from 2.85 (Mar 24) to 3.88, marking an increase of 1.03.
- For EV / EBITDA (X), as of Mar 25, the value is 19.68. This value exceeds the healthy maximum of 15. It has increased from 17.89 (Mar 24) to 19.68, marking an increase of 1.79.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.04. This value exceeds the healthy maximum of 3. It has increased from 2.63 (Mar 24) to 4.04, marking an increase of 1.41.
- For Retention Ratios (%), as of Mar 25, the value is 92.54. This value exceeds the healthy maximum of 70. It has increased from 87.55 (Mar 24) to 92.54, marking an increase of 4.99.
- For Price / BV (X), as of Mar 25, the value is 4.92. This value exceeds the healthy maximum of 3. It has decreased from 6.06 (Mar 24) to 4.92, marking a decrease of 1.14.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.04. This value exceeds the healthy maximum of 3. It has increased from 2.63 (Mar 24) to 4.04, marking an increase of 1.41.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Artemis Medicare Services Ltd:
- Net Profit Margin: 8.77%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 12.23% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 10.74% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.57
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.45
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 41 (Industry average Stock P/E: 84.07)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.31
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 8.77%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | Plot No. 14, Delhi Delhi 110075 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Onkar Kanwar | Chairman & Non-Exe.Director |
| Dr.(Mrs.) Devlina Chakravarty | Managing Director |
| Mr. Neeraj Kanwar | Non Executive Director |
| Mrs. Shalini Kanwar Chand | Non Executive Director |
| Mr. Sunam Sarkar | Non Executive Director |
| Ms. Deepa Gopalan Wadhwa | Independent Director |
| Mr. Sunil Tandon | Independent Director |
| Mr. Sanjib Sen | Independent Director |
| Mr. Vinod Rai | Independent Director |
| Mr. Akshaykumar Narendrasinhji Chudasama | Independent Director |
| Ms. Pallavi Shardul Shroff | Independent Director |
FAQ
What is the intrinsic value of Artemis Medicare Services Ltd?
Artemis Medicare Services Ltd's intrinsic value (as of 01 February 2026) is ₹332.39 which is 34.57% higher the current market price of ₹247.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹3,912 Cr. market cap, FY2025-2026 high/low of ₹335/208, reserves of ₹873 Cr, and liabilities of ₹1,416 Cr.
What is the Market Cap of Artemis Medicare Services Ltd?
The Market Cap of Artemis Medicare Services Ltd is 3,912 Cr..
What is the current Stock Price of Artemis Medicare Services Ltd as on 01 February 2026?
The current stock price of Artemis Medicare Services Ltd as on 01 February 2026 is ₹247.
What is the High / Low of Artemis Medicare Services Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Artemis Medicare Services Ltd stocks is ₹335/208.
What is the Stock P/E of Artemis Medicare Services Ltd?
The Stock P/E of Artemis Medicare Services Ltd is 41.0.
What is the Book Value of Artemis Medicare Services Ltd?
The Book Value of Artemis Medicare Services Ltd is 63.8.
What is the Dividend Yield of Artemis Medicare Services Ltd?
The Dividend Yield of Artemis Medicare Services Ltd is 0.18 %.
What is the ROCE of Artemis Medicare Services Ltd?
The ROCE of Artemis Medicare Services Ltd is 14.9 %.
What is the ROE of Artemis Medicare Services Ltd?
The ROE of Artemis Medicare Services Ltd is 12.9 %.
What is the Face Value of Artemis Medicare Services Ltd?
The Face Value of Artemis Medicare Services Ltd is 1.00.